Stockscreener 앱 받기
0.49
0.08%
0.0004
시간 외 거래:
.47
-0.02
-4.08%
전일 마감가:
$0.4896
열려 있는:
$0.51
하루 거래량:
164.13K
Relative Volume:
0.44
시가총액:
$34.79M
수익:
$391.70K
순이익/손실:
$-52.34M
주가수익비율:
-0.6533
EPS:
-0.75
순현금흐름:
$-45.92M
1주 성능:
-3.92%
1개월 성능:
-14.89%
6개월 성능:
-56.25%
1년 성능:
-83.33%
1일 변동 폭
$0.463
$0.51
1주일 범위
$0.463
$0.58
52주 변동 폭
$0.463
$3.45
Ovid Therapeutics Inc Stock (OVID) Company Profile
명칭
Ovid Therapeutics Inc
전화
212-776-4381
주소
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
OVID을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
0.49 | 34.79M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-18 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-04-30 | 개시 | B. Riley Securities | Buy |
| 2024-04-29 | 개시 | H.C. Wainwright | Buy |
| 2024-04-05 | 개시 | Wedbush | Outperform |
| 2023-12-21 | 개시 | BTIG Research | Buy |
| 2023-10-13 | 개시 | Oppenheimer | Outperform |
| 2021-04-20 | 다운그레이드 | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-02 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | 개시 | RBC Capital Mkts | Outperform |
| 2018-04-20 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Ovid Therapeutics Inc 주식(OVID)의 최신 뉴스
Ovid Therapeutics earnings beat by $0.04, revenue fell short of estimates - Investing.com UK
Ovid Therapeutics stock plunges to 52-week low of $0.46 - Investing.com India
Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Ovid Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
We're A Little Worried About Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate - Yahoo Finance
Ovid Therapeutics (OVID) Expected to Announce Earnings on Friday - Defense World
Trump's FDA chief pick Makary to face overhauling agency, keeping Kennedy happy -March 06, 2025 at 06:00 am EST - Marketscreener.com
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.03 Consensus Target Price from Brokerages - Defense World
Ovid Therapeutics appoints new board member and updates compensation policy - Investing.com India
Ovid Therapeutics appoints new board member and updates compensation policy By Investing.com - Investing.com South Africa
Ovid Therapeutics Expands Board with New Appointment - TipRanks
Ovid Therapeutics Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
Ovid Therapeutics Appoints Dr. Stelios Papadopoulos To Board - citybiz
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors - GlobeNewswire
Ovid therapeutics CBFO sells $2,185 in stock - Investing.com India
Ovid therapeutics CBFO sells $2,185 in stock By Investing.com - Investing.com Australia
Ovid therapeutics president and COO sells $2,956 in stock By Investing.com - Investing.com Canada
Ovid therapeutics president and COO sells $2,956 in stock - Investing.com India
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Want Insights on Brain Condition Treatments? Ovid Therapeutics Set for Major Healthcare Conference - StockTitan
Ovid Therapeutics stock hits 52-week low at $0.55 - Investing.com India
Ovid Therapeutics stock hits 52-week low at $0.55 By Investing.com - Investing.com UK
Epilepsy Market Assessment in the 7MM by 2034 — A Detailed Analysis of Growth Prospects Across Different Types | DelveInsight - GlobeNewswire Inc.
Analyzing Madrigal Pharmaceuticals (NASDAQ:MDGL) & Ovid Therapeutics (NASDAQ:OVID) - Defense World
Dup15q Syndrome Market Expected to rise, 2032 | Ovid - openPR
SG Americas Securities LLC Purchases 17,172 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Ovid Therapeutics faces Nasdaq delisting over share price - MSN
Ovid Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com South Africa
Ovid Therapeutics IncReceives Nasdaq Notice For Minimum Bid Price Non-Compliance - Marketscreener.com
Ovid stock plunges to 52-week low, touches $0.59 amid downturn - MSN
Ovid therapeutics president and COO acquires $4,971 in stock - MSN
Dup15q Syndrome Drugs Market Size Report 2032 | Ovid - openPR
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Epilepsy Market Expected to rise, 2034 | Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven - Barchart
Healthcare Spotlight: Ovid Therapeutics Takes Center Stage at Major Oppenheimer Conference - StockTitan
Ovid Therapeutics (NASDAQ:OVID) Upgraded by Oppenheimer to Outperform Rating - MarketBeat
Oppenheimer raises Ovid stock rating, sets $4 price target - MSN
Ovid Therapeutics stock hits 52-week low at $0.68 amid downturn - MSN
Ovid upgraded to outperform by Oppenheimer, OV329 cited - MSN
Ovid Therapeutics upgraded at Oppenheimer as OV329’s promise ‘quite real’ - Yahoo Finance
Ovid Therapeutics Inc (OVID) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.14%
2.83%
자본화:
|
볼륨(24시간):